Patents by Inventor Dennis Shinji Yamashita

Dennis Shinji Yamashita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210061812
    Abstract: The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.
    Type: Application
    Filed: February 15, 2018
    Publication date: March 4, 2021
    Inventors: Aimee CROMBIE SPEERSCHNEIDER, Dennis SHINJI YAMASHITA, Philip Michael PITIS, Michael John HAWKINS, Guodong Liu, Tamara Ann MISKOWSKI DAUBERT, Catherine C.K. YUAN, Robert BORBO KARGBO, Robert Jason HERR, Donna ROMERO
  • Publication number: 20210061790
    Abstract: The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.
    Type: Application
    Filed: February 15, 2018
    Publication date: March 4, 2021
    Inventors: Aimee CROMBIE SPEERSCHNEIDER, Dennis SHINJI YAMASHITA, Philip Michael PITIS, Michael John HAWKINS, Guodong Liu, Tamara Ann MISKOWSKI DAUBERT, Catherine C.K. YUAN, Robert BORBO KARGBO, Robert Jason HERR, Donna ROMERO
  • Publication number: 20200231564
    Abstract: The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.
    Type: Application
    Filed: February 27, 2019
    Publication date: July 23, 2020
    Inventors: Aimee Crombie Speerschneider, Dennis Shinji Yamashita, Philip Michael Pitis, Michael John Hawkins, Guodong Liu, Tamara Ann Miskowski Daubert, Catherine C.K. Yuan, Robert Borbo Kargbo, Robert Jason Herr, Donna Romero, Gregory J. Pacofsky
  • Publication number: 20190202803
    Abstract: The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.
    Type: Application
    Filed: February 27, 2019
    Publication date: July 4, 2019
    Inventors: Aimee Crombie Speerschneider, Dennis Shinji Yamashita, Philip Michael Pitis, Michael John Hawkins, Guodong Liu, Tamara Ann Miskowski Daubert, Catherine C.K. Yuan, Robert Borbo Kargbo, Robert Jason Herr, Donna Romero, Gregory J. Pacofsky
  • Patent number: 10246436
    Abstract: The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: April 2, 2019
    Assignee: TREVENA, INC.
    Inventors: Aimee Crombie Speerschneider, Dennis Shinji Yamashita, Philip Michael Pitis, Michael John Hawkins, Guodong Liu, Tamara Ann Miskowski Daubert, Catherine C. K. Yuan, Robert Borbo Kargbo, Robert Jason Herr, Donna Romero, Gregory J. Pacofsky
  • Publication number: 20170210725
    Abstract: The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.
    Type: Application
    Filed: August 30, 2016
    Publication date: July 27, 2017
    Inventors: Aimee Crombie Speerschneider, Dennis Shinji Yamashita, Philip Michael Pitis, Michael John Hawkins, Guodong Liu, Tamara Ann Miskowski Daubert, Catherine C.K. Yuan, Robert Borbo Kargbo, Robert Jason Herr, Donna Romero, Gregory J. Pacofsky
  • Patent number: 7491728
    Abstract: The pyrimidinone compounds are disclosed. Methods of preparing the pyrimidinone compounds are also disclosed.
    Type: Grant
    Filed: April 7, 2004
    Date of Patent: February 17, 2009
    Assignee: SmithKline Beecham Corp.
    Inventors: Irina V. Shcherbakova, Manuel F. Balanddrin, Guangfei Huang, Otto Geoffroy, John Fox, Robert Marquis, Dennis Shinji Yamashita, Juan Luengo, Wenyong Wang
  • Patent number: 7405209
    Abstract: The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: July 29, 2008
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Robert Wells Marquis, Jr., Yu Ru, Daniel Frank Veber, Maxwell David Cummings, Scott Kevin Thompson, Dennis Shinji Yamashita
  • Publication number: 20040002487
    Abstract: The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
    Type: Application
    Filed: April 1, 2003
    Publication date: January 1, 2004
    Inventors: Robert Wells Marquis, Yu Ru, Daniel Frank Veber, Maxwell David Cummings, Scott Kevin Thompson, Dennis Shinji Yamashita
  • Publication number: 20030225061
    Abstract: The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
    Type: Application
    Filed: April 1, 2003
    Publication date: December 4, 2003
    Inventors: Robert Wells Marquis, Yu Ru, Daniel Frank Veber, Maxwell David Cummings, Scott Kevin Thompson, Dennis Shinji Yamashita
  • Publication number: 20030144175
    Abstract: The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
    Type: Application
    Filed: June 14, 2001
    Publication date: July 31, 2003
    Applicant: SmithKline Beecham Corporation
    Inventors: Robert Wells Marquis, Yu Ru, Daniel Frank Veber, Maxwell David Cummings, Scott Kevin Thompson, Dennis Shinji Yamashita
  • Patent number: 6586466
    Abstract: The present invention provides compounds which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
    Type: Grant
    Filed: April 20, 2001
    Date of Patent: July 1, 2003
    Assignee: SmithKline Beecham Corporation
    Inventor: Dennis Shinji Yamashita
  • Patent number: 6562842
    Abstract: The present invention provides compounds which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: May 13, 2003
    Assignee: SmithKline Beecham Corporation
    Inventor: Dennis Shinji Yamashita
  • Patent number: 6518267
    Abstract: The present invention provides bis-aminomethyl carbonyl protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: February 11, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: William Edward Bondinell, Renee Louise DesJarlais, Daniel Frank Veber, Dennis Shinji Yamashita
  • Publication number: 20020173469
    Abstract: The present invention provides compounds which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
    Type: Application
    Filed: May 30, 2002
    Publication date: November 21, 2002
    Applicant: SmithKline Beecham Corporation
    Inventor: Dennis Shinji Yamashita
  • Publication number: 20020147188
    Abstract: The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
    Type: Application
    Filed: February 13, 2002
    Publication date: October 10, 2002
    Applicant: SmithKline Beecham Corporation
    Inventors: Robert Wells Marquis, Yu Ru, Daniel Frank Veber, Maxwell David Cummings, Scott Kevin Thompson, Dennis Shinji Yamashita
  • Publication number: 20020077455
    Abstract: The present invention provides compounds which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
    Type: Application
    Filed: April 20, 2001
    Publication date: June 20, 2002
    Applicant: SmithKline Beecham Corporation
    Inventor: Dennis Shinji Yamashita
  • Publication number: 20020065230
    Abstract: The present invention provides bis-aminomethylcarbonyl compounds that are inhibitors of cysteine and serine proteases. The compounds are particularly useful for treating diseases in which excess cysteine protease activity has been implicated, including osteoporosis, periodontitis and arthritis.
    Type: Application
    Filed: January 22, 2002
    Publication date: May 30, 2002
    Applicant: SmithKline Beecham Corporation
    Inventors: William Edward Bondinell, Renee Louise Desjarlais, Daniel Frank Veber, Dennis Shinji Yamashita
  • Patent number: 6331542
    Abstract: The present invention provides compounds which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
    Type: Grant
    Filed: April 19, 2000
    Date of Patent: December 18, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Thomas Joseph Carr, Renee Louise Desjarlais, Timothy Francis Gallagher, Stacie Marie Halbert, Hye-Ja Oh, Scott Kevin Thompson, Daniel Frank Veber, Dennis Shinji Yamashita, Jack Hwekwo Yen
  • Patent number: 6232342
    Abstract: The present invention provides compounds which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease, hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting and bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
    Type: Grant
    Filed: June 11, 1999
    Date of Patent: May 15, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Thomas Joseph Carr, Renee Louise Desjarlais, Timothy Francis Gallagher, Stacie Marie Halbert, Hye-Ja Oh, Scott Kevin Thompson, Daniel Frank Veber, Dennis Shinji Yamashita, Jack Hwekwo Yen